Drug Trial Radar · NCT02004704
A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Last checked: Nov 20, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Dec 4, 2013
Primary completion
Sep 6, 2023
Study completion Sep 6, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa. The secondary objectives of this study were to obtain data regarding the efficacy of olipudase alfa and to characterize olipudase alfa pharmacodynamics (PD) and pharmacokinetics (PK) following long-term administration.
Conditions
- Sphingomyelin Lipidosis
Interventions
GZ402665Drug
Pharmaceutical form: Powder for concentrate for solution for infusion Route of administration: intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) Except Infusion-Associated Reactions (IARs)Time frame: From the signature of informed consent up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- Number of Participants With IARsTime frame: From the signature of informed consent up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- For Adults: Number of Participants With Abnormality in Complete Physical Examinations Including Abbreviated Physical ExamTime frame: Baseline (Day 1 of original study), Month 78
- For Pediatrics: Number of Participants With Abnormality in Complete Physical Examinations Including Abbreviated Physical ExamTime frame: Baseline (Day 1 of original study), Month 84
- For Adults: Number of Participants With Abnormality in Extended Neurological ExaminationsTime frame: Baseline (Day 1 of original study), Month 78
- For Pediatrics: Number of Participants With Abnormality in Extended Neurological ExaminationsTime frame: Baseline (Day 1 of original study), Month 84
- Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital SignsTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- Number of Participants With PCSA in Clinical Chemistry ParametersTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- Number of Participants With PCSA in Liver Function TestsTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- Number of Participants With PCSA in Hematology ParametersTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- Number of Participants With PCSA in Electrocardiogram (ECG)Time frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
- For Adults: Percent Change From Baseline in Pre-Infusion Plasma Ceramide at Month 90Time frame: Baseline (Day 1 of original study) and Month 90 (pre-infusion)
- For Pediatrics: Percent Change From Baseline in Pre-Infusion Plasma Ceramide at Month 66Time frame: Baseline (Day 1 of original study) and Month 66 (pre-infusion)
- Participants From Adult Study DFI13412: Number of Participants With Abnormal Liver BiopsyTime frame: Baseline (Day 1 of original study) and Month 36
- Participants From Pediatric Study DFI13803: Number of Participants With Abnormalities in Liver Ultrasound DopplerTime frame: Baseline (Day 1 of original study), Week 2 and Months 12, 18 and 24
- Number of Participants With Anti-Drug Antibodies (ADA) Against Olipudase AlfaTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Investigational Site Number 840001
New York, New York
Investigational Site Number 056001
Leuven, Belgium
Investigational Site Number 076001
Porto Alegre, Brazil
Investigational Site Number 250002
Bron, France
Investigational Site Number 276002
Hochheim am Main, Germany
Investigational Site Number 380002
Sassari, Italy
Investigational Site Number 380001
Udine, Italy
Investigational Site Number 826001
London, United Kingdom
Investigational Site Number 826002
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.